The first Rubius Therapeutics trade was made in Q2 2019.
Since then Ken Griffin bought shares six more times and sold shares on seven occasions. The investor completely sold their stake between Q3 2022 and Q1 2023.
Avg closing price
Price range
Sold -132k shares
Q1 2023
Avg closing price
$0.15
Price range
$0.02
-
$0.34
Sold 6.7% shares (-9.46k shares)
Q4 2022
Avg closing price
$0.27
Price range
$0.14
-
$0.45
Sold 59.8% shares (-211k shares)
Q3 2022
Avg closing price
$0.75
Price range
$0.43
-
$1.29
Increased shares by 22.3% (+64.3k shares)
Q2 2022
Avg closing price
$1.68
Price range
$0.79
-
$5.98
Increased shares by 374.2% (+228k shares)
Q1 2022
Avg closing price
$6.35
Price range
$4.25
-
$10.40
Increased shares by 219.4% (+41.8k shares)
Q4 2021
Avg closing price
$13.87
Price range
$9.68
-
$17.74
New holding (+19k shares)
Q3 2021
Avg closing price
$21.75
Price range
$17.60
-
$25.91
Sold -83.3k shares
Q1 2021
Avg closing price
$14.61
Price range
$8.02
-
$32.00
Increased shares by 147.1% (+49.6k shares)
Q3 2020